Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $253.96
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 7, 26 | Farrell Michael J. | director, officer: Chairman and CEO | M-Exempt | 4,991 @ $146.34 | $730.4K |
| Sep 15, 26 |
| RBC Capital |
| upgrade |
| Sector Perform |
| Outperform |
| Aug 31, 26 | Keybanc | maintain | Overweight | Overweight |
| Aug 7, 26 | Keybanc | maintain | Overweight | Overweight |
| Aug 7, 26 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| Aug 7, 26 | Piper Sandler | maintain | Neutral | Neutral |
| Aug 7, 26 | RBC Capital | maintain | Sector Perform | Sector Perform |
| Jul 15, 26 | Mizuho | maintain | Outperform | Outperform |
| Jul 13, 26 | Citigroup | downgrade | Buy | Neutral |
| Jul 10, 26 | Jefferies | maintain | Hold | Hold |
| Oct 7, 26 |
| Farrell Michael J. |
| director, officer: Chairman and CEO |
| S-Sale |
| 4,991 @ $226.33 |
| $1.13M |
| Oct 7, 26 | Farrell Michael J. | director, officer: Chairman and CEO | M-Exempt | 4,991 @ $146.34 | $730.4K |
| Sep 8, 26 | Farrell Michael J. | director, officer: Chairman and CEO | 0 | — |
| Aug 14, 26 | Leong Justin | officer: Chief Product Officer | A-Award | 6,461 | — |
| Aug 14, 26 | Rider Michael J | officer: Global General Counsel | A-Award | 3,230 | — |
| Aug 14, 26 | Farrell Michael J. | director, officer: Chairman and CEO | A-Award | 13,547 | — |
| Aug 14, 26 | Bloomer Aaron | officer: Chief Financial Officer | A-Award | 9,072 | — |
FY2024 · 10-K disclosure
FY2024 · 10-K disclosure
Stock news · updated daily
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
RMD heads into Q1 fiscal 2027 earnings with sleep device demand and new product launches supporting growth, while MatrixCare's divestiture weighs on revenues.
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced the U.S. launch of AirTouch F40, the newest addition to its growing portfolio of fabric continuous positive airway pressure (CPAP) masks. Designed for people with obstructive sleep apnea (OSA) to provide greater comfort and choice in therapy1, the AirTouch F40 helps address key factors that can influence long-term adherence.
I track an investable universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and future return potential. Applied Materials, D.R. Horton, and Home Depot saw notable ranking improvements due to upgraded EPS growth estimates and/or favorable valuation shifts. 44 out of 50 stocks currently offer a forward return estimate of at least 10%, with 32 appearing potentially undervalued based on free cash flow mean reversion.
ResMed Inc. (NYSE: RMD - Get Free Report) CEO Michael Farrell sold 4,991 shares of the business's stock in a transaction that occurred on Wednesday, October 7th. The stock was sold at an average price of $226.33, for a total value of $1,129,613.03. Following the sale, the chief executive officer directly owned 479,803 shares in the
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2027 on Thursday, October 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
ResMed (NYSE: RMD) outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing product innovation in sleep and respiratory care. Chairman and Chief Executive Officer Mick Farrell said the company has issued guidance for 5% to 7% core constant-currency revenue growth, including an
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | 2.89 | 2.95 | Beat 2.1% | $1.46B |
| Apr 30, 2026 | 2.80 | 2.86 | Beat 2.1% | $1.43B |
| Jan 29, 2026 | 2.74 | 2.81 | Beat 2.6% | $1.42B |
| Oct 30, 2025 | 2.51 | 2.55 | Beat 1.6% | $1.34B |
| Jul 31, 2025 | 2.46 | 2.55 | Beat 3.7% | $1.35B |
| Apr 23, 2025 | 2.38 | 2.37 | Miss -0.4% | $1.29B |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 8, 2026 | 2026-10-08 17:31:36 | View |
| ARS | Oct 1, 2026 | 2026-10-01 16:37:10 | View |
| DEFA14A | Oct 1, 2026 | 2026-10-01 16:35:46 | View |
| DEF 14A | Oct 1, 2026 | 2026-10-01 16:34:04 | View |
| 4/A | Oct 1, 2026 | 2026-10-01 16:29:28 | View |
| 4 | Oct 1, 2026 | 2026-10-01 16:27:25 | View |
| 4 | Oct 1, 2026 | 2026-10-01 16:23:00 | View |
| 4 | Oct 1, 2026 | 2026-10-01 16:19:22 | View |
| 4 | Oct 1, 2026 | 2026-10-01 16:08:37 | View |
| 4 | Sep 10, 2026 | 2026-09-10 06:40:28 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | RMD | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 24.3x | 29.5x · sector 20.7x | Elevated |
| Forward P/E (FY27E) | 21.0x | EPS est. 12.10 | In line |
| Price / Book | 5.6x | 6.6x | Discount |
| Price / Sales | 6.3x | 6.9x | In line |
| EV / EBITDA | 16.2x | 20.4x | Discount |
| Return on equity | 23.9% | — | Top tier |
| Gross margin | 61.2% | 57.9% | In line |
| Debt / Equity | 0.13 | 0.22 | Conservative |
| Piotroski / Altman Z | 6/9 | Z 11.64 | Safe zone |
Discounted cash flow model
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 78.08 | Oscillator | Sell |
| Stochastic %K (14, 3, 3) | 95.23 | Oscillator | Sell |
| Williams %R (14) | -4.87 | Oscillator | Sell |
| MACD (12, 26, 9) | 6.85 (Hist 2.45) | Oscillator | Strong Buy |
| Average Directional Index (14) | 30.71 (+DI 35.4 / -DI 8.6) | Trend | Strong Buy |
| EMA 20 | 236.89 | MA | Strong Buy |
| SMA 20 | 232.84 | MA | Strong Buy |
| EMA 50 | 228.96 | MA | Strong Buy |
| SMA 50 | 229.55 | MA | Strong Buy |
| SMA 200 | 225.08 | MA | Strong Buy |